Funding for this research was provided by:
Auckland Medical Research Foundation (1115015)
Received: 24 May 2022
Accepted: 17 August 2022
First Online: 5 September 2022
: The collection of human bone samples was approved by the New Zealand Ministry of Health and Disability Ethics Committee (HDEC approval no. NTX/05/06/058<i>).</i> All study participants provided their written informed consent.
: Not applicable.
: Nicola Dalbeth has received consulting fees, speaker fees or grants from AstraZeneca, Dyve Biosciences, Horizon, Amgen, Selecta, Arthrosi, JW Pharmaceutical Corporation, PK Med, PTC Therapeutics, Protalix, Cello Health, Abbvie, and Janssen, outside the submitted work. The other authors declare that they have no competing interests.